KR20180069528A - Cosmetic Composition for comprising longanae arillus extracts - Google Patents
Cosmetic Composition for comprising longanae arillus extracts Download PDFInfo
- Publication number
- KR20180069528A KR20180069528A KR1020160171795A KR20160171795A KR20180069528A KR 20180069528 A KR20180069528 A KR 20180069528A KR 1020160171795 A KR1020160171795 A KR 1020160171795A KR 20160171795 A KR20160171795 A KR 20160171795A KR 20180069528 A KR20180069528 A KR 20180069528A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- extract
- present
- cosmetic composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 239000000284 extract Substances 0.000 title claims abstract description 100
- 239000002537 cosmetic Substances 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 38
- 230000037303 wrinkles Effects 0.000 claims abstract description 36
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 32
- 230000006872 improvement Effects 0.000 claims abstract description 26
- 230000037394 skin elasticity Effects 0.000 claims abstract description 25
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 108010035532 Collagen Proteins 0.000 claims description 20
- 102000008186 Collagen Human genes 0.000 claims description 20
- 229920001436 collagen Polymers 0.000 claims description 20
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 18
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000008234 soft water Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 14
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 abstract description 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 abstract description 2
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 67
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 19
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 18
- 235000006008 Brassica napus var napus Nutrition 0.000 description 18
- 240000000385 Brassica napus var. napus Species 0.000 description 18
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 18
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 18
- 239000002904 solvent Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 235000013376 functional food Nutrition 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000003889 eye drop Substances 0.000 description 10
- 241000282465 Canis Species 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000686 essence Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 108010014258 Elastin Proteins 0.000 description 7
- 102000016942 Elastin Human genes 0.000 description 7
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229920002549 elastin Polymers 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- -1 fatty acid esters Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- GFVYDNHWTCHDSN-UHFFFAOYSA-N 14-methylpentadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C GFVYDNHWTCHDSN-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 241001093760 Sapindaceae Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 210000000720 eyelash Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 240000001008 Dimocarpus longan Species 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000000235 Euphoria longan Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- 235000010624 Medicago sativa Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000613447 Dimocarpus Species 0.000 description 1
- 235000000522 Dimocarpus Nutrition 0.000 description 1
- 235000000525 Dimocarpus longan Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910000063 azene Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 용안육 추출물을 포함하는 화장료 조성물에 관한 것으로서, 보다 상세하게는 피부 탄력 증진, 주름 개선, 보습, 또는 피부 트러블 개선 등의 우수한 효과를 가지는 화장료 조성물에 관한 것이다. 또한, 본 발명은 용안육 추출물을 포함하는 식품 조성물 및 의약외품 조성물에 관한 것이다.More particularly, the present invention relates to a cosmetic composition having excellent effects such as skin elasticity enhancement, wrinkle improvement, moisturizing, or skin trouble improvement. In addition, the present invention relates to a food composition and a quasi-drug composition comprising a canola extract.
콜라겐은 피부의 섬유아세포(Fibroblast)에서 생성되는 주요 기질 단백질로서 세포 외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포 분할과 분화(유기체의 성장 혹은 상처 치유 시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 콜라겐을 분해하는 콜라게나제 효소 활성으로 콜라겐 감소가 촉진된다. 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다.Collagen is a major substrate protein produced in the fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical durability of the skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, cell division and differentiation (Induction of growth of an organism or wound healing) are known. Such collagen is reduced by photoaging by age and ultraviolet irradiation, and collagenase activity, which degrades collagen, promotes collagen reduction. This is known to be closely related to the formation of wrinkles in the skin.
또한, 엘라스틴(Elastin) 섬유는 콜라겐과 가교 결합을 형성하며 피부 탄력에 관여하고 있는 주름 생성에 중요한 피부 구성성분이다. 엘라스틴 섬유의 결핍과 응집, 엘라스틴 분해 효소인 엘라스타제(Elastase)의 활성도의 현격한 증가는 피부 주름 생성 요인 중의 하나로 밝혀지고 있다. 엘라스타제는 엘라스틴을 분해할 수 있는 유일한 효소로서 이에 대한 저해는 피부 주름 개선을 근본적으로 줄여줄 수 있다고 알려져 있다.In addition, Elastin fiber forms crosslinks with collagen and is a skin constituent important for wrinkle formation involved in skin elasticity. The deficiency and aggregation of elastin fibers and the dramatic increase in the activity of the elastin degrading enzyme Elastase have been found to be one of the causes of skin wrinkles. Elastase is the only enzyme capable of degrading elastin, and inhibition of it is known to be able to radically reduce wrinkles.
아울러, 콜라겐 및 엘라스틴 섬유는 진피층 내의 수분 보유에 중요한 역할을 하는 기질 단백질로 이러한 기질 단백질이 수분을 흡착하며, 이들이 이루는 구조 내부에 수분 보유력을 높여 피부가 적정 수분을 함유한 상태를 유지할 수 있도록 해주며, 이를 통해 피부의 탄력을 유지하는데 관여한다고 알려져 있다.In addition, collagen and elastin fibers are substrate proteins that play an important role in moisture retention in the dermal layer. These protein proteins adsorb moisture and increase the water holding capacity inside the structure to maintain the skin's proper moisture content. And it is known to be involved in maintaining the elasticity of the skin.
현재, 피부 탄력 증진 및 주름 개선 화장료로는 레티노이드, 아데노신, 동물태반유래 단백질, 클로렐라 추출물 등이 알려져 있다. 가장 잘 알려져 있는 레티놀은 콜라겐 합성을 촉진하며 엘라스타제 효소를 저해하는 물질이지만 불안정하며, 피부 적용 시 자극, 발적 등의 안전성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 효과가 미미하여 실질적으로 피부 탄력 증진 및 주름 개선 효과를 기대하기가 어렵다고 알려져 있다.At present, retinoids, adenosine, animal placenta-derived proteins, chlorella extract, and the like are known as cosmetics for improving skin elasticity and improving wrinkles. The best known retinol promotes collagen synthesis and is a substance that inhibits elastase enzyme, but it is unstable. When applied to the skin, there is a limitation in usage due to safety problems such as irritation and redness, and chlorella extract has little effect, It is known that it is difficult to expect the effect of improving elasticity and wrinkle.
화장품은 피부를 보호하고 피부의 미화 및 청결을 위해 사용되는 제품이지만, 그 조성으로는 피부 보호 목적과는 상이한 성분들이 제품 형성을 위해 불가피하게 포함된다. 이러한 성분들로는 계면활성제, 방부제, 향료, 자외선 차단제, 색소뿐 아니라, 그 밖의 효능 및 효과를 부여하기 위한 여러 가지 성분들이 여기에 포함된다. 이들 성분은 일반적으로 피부에 염증이나 뾰루지, 부종 등 각종 트러블을 발생시키는 것으로 알려져 있다(Maibach. H. I., Contact Dermatitis, 6. 369-404, 1980). 또한, 체내로부터 배출되는 피지 및 땀, 화장품 성분 중의 지방산, 고급 알코올, 단백질 성분 등이 피부상에 존재하는 피부 상재균에 의해 독성이 강한 물질로 분해되어 이들에 의해 피부 염증이 유발될 수도 있으며, 태양으로부터 나오는 자외선에 의해서도 피부 염증이 유발된다는 것은 잘 알려진 사실이다.Cosmetics are products used to protect the skin and beautify and clean the skin, but the composition thereof inevitably includes ingredients that are different from the purpose of skin protection. These ingredients include surfactants, preservatives, fragrances, sunscreens, pigments, as well as various ingredients for imparting other efficacy and effects. These ingredients are generally known to cause skin irritation, rashes, swelling and other problems (Maibach, H., I. Contact Dermatitis, 6. 369-404, 1980). In addition, sebum and sweat discharged from the body, fatty acids in cosmetic ingredients, higher alcohols, protein components and the like may be decomposed into substances having high toxicity by the skin-on-ground bacteria existing on the skin, It is well known that skin inflammation is caused by ultraviolet rays from the sun.
염증 반응은 붉어짐(feeling of redness), 따끔거림(pricking feeling), 화끈거림(burning hotness), 팽윤(swelling), 조직의 변화와 같은 5가지 현상으로 나타나는데, 이는 해로운 주위 환경, 즉 세균과 같은 외부 물질의 침입과 기계적 손상으로부터 생체를 보호하려는 생리적인 반응이다. 이러한 염증현상은 여러 종류의 다형핵 백혈구(PMNs)와 면역 물질의 많은 증가를 초래하며, 이처럼 증가된 세포들은 염증성 세포 산물인 다양한 종류의 단백질 분해 효소와 사이토카인 등을 분비함으로써 치료 및 방어를 할 수 있게 해준다. 그러나, 이러한 작용은 인접해 있는 조직 세포와 비세포 성분들에 해로운 손상을 일으키기도 한다. 따라서, 적절한 조건 하에서는 염증 초기 상태가 지난 후 정상 기능을 되찾게 되지만, 염증을 자극하는 자극제가 없어지지 않거나 계속해서 만들어질 경우에는 결과적으로 만성 염증이 일어나게 되어 더욱더 심각한 조직의 손상을 가져온다.Inflammation reactions are manifested in five phenomena, such as feeling of redness, pricking feeling, burning hotness, swelling, and tissue changes, which may be caused by harmful environmental conditions, It is a physiological reaction to protect a living body from intrusion and mechanical damage. These inflammatory phenomena lead to a large number of polymorphonuclear leukocytes (PMNs) and immune substances, and these increased cells secrete a variety of inflammatory cell products, proteases and cytokines. I can do it. However, this action may cause harmful damage to adjacent tissue cells and non-cellular components. Therefore, under proper conditions, the normal function is restored after the initial state of inflammation. However, if irritant stimulating agents are not eliminated or continuously produced, chronic inflammation occurs as a result, resulting in more serious tissue damage.
한편, 용안육 (Longanae Arillus)은 용안 (龍眼) Dimocarpus longan Loureiro (무환자과 Sapindaceae)의 헛씨껍질이다. 구체적으로 용안육은 무환자나무과(Sapindaceae)의 상록교목이고 열매의 용안의 과육을 말한다. 즉 과육같이 보이는 투명한 가종피(arillus)이며 마르면 검은 갈색인 용안육(Lonaganae Arillus)이 된다. 용안육은 주로 중국, 동남아 지역에 분포, 자생하며, 진정, 건위, 자양작용이 있으며, 불면증에 효과가 있다. 용안육 이외에 계원(桂圓), 교루(鮫淚), 밀비(蜜脾), 아려지(亞枝), 여주(驪珠), 연란(燕卵), 용목(龍目), 용안(龍眼), 용안건(龍眼乾), 원안(圓眼), 원안육(元眼肉), 익지(益智),천탄자(川彈子), 여지노(枝奴)로 명명될 수 있다.On the other hand, yonganyuk (Longanae Arillus ) is the dragon eye Dimocarpus It is the scabbard of longan Loureiro (moth and Sapindaceae). Specifically, yonggan is an evergreen tree of Sapindaceae and refers to the pulp of the fruit. That is to say, the transparent pulp ( arillus ) appears to be pulpy, and when dried, it becomes a black brown lonaganae arillus . Yongtan is mainly distributed in China and Southeast Asia, has a natural, calm, dry, nurturing effect and is effective for insomnia. In addition to Yongan, it is also known as Kwangwen, Shark 淚, Milby, Arjie, Yeoju, Yan, Dragon 龍, Yongan, It can be named as an agan, an uan, an original 肉, an 益 智, a 子 子, a 지).
이러한 배경하에, 본 발명자들은 천연에 존재하는 천연 자원들로부터 피부 탄력 증진, 주름 개선, 보습, 및 피부 트러블 개선 효과가 우수한 물질에 관하여 연구를 수행하였으며, 이에 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 조성물이 콜라겐 합성 촉진, 엘라스타제 활성 저해, 항염증 및 보습 효과를 나타냄을 규명하여, 이를 활용한 화장료 조성물, 식품 조성물 및 의약외품 조성물을 완성하기에 이르렀다.Under these circumstances, the inventors of the present invention conducted studies on substances having superior skin elasticity, wrinkle improvement, moisturizing effect and skin trouble improving effect from natural natural resources. , The composition of the present invention has been shown to exhibit collagen synthesis promotion, inhibition of elastase activity, antiinflammation and moisturizing effect, and the cosmetic composition, food composition and quasi-drug composition utilizing the composition have been completed.
본 발명의 목적은 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition comprising a canola extract or a fraction thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공하는 것이다.More specifically, it is an object of the present invention to provide a cosmetic composition for skin elasticity enhancement or wrinkle improvement comprising a canola extract or a fraction thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공하는 것이다.More specifically, the object of the present invention is to provide a cosmetic composition for moisturizing the skin, which comprises a canola extract or a fraction thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 트러블 개선용 화장료 조성물을 제공하는 것이다.More specifically, it is an object of the present invention to provide a cosmetic composition for improving skin troubles comprising a canola extract or a fraction thereof as an active ingredient.
본 발명의 다른 목적은 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition comprising a canola extract or a fraction thereof as an active ingredient.
본 발명의 또 다른 목적은 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 의약외품 조성물을 제공하는 것이다.It is still another object of the present invention to provide a quasi-drug composition comprising a canola extract or a fraction thereof as an active ingredient.
본 발명은 상기와 같은 과제들을 해결하고, 본 발명의 목적을 달성하기 위하여 용안육 추출물 또는 이의 분획물을 포함하는 화장료 조성물을 제공한다.Disclosure of Invention Technical Problem [6] The present invention provides a cosmetic composition comprising a lucerne extract or a fraction thereof to solve the above problems and to achieve the object of the present invention.
본 발명의 다른 양태로서 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공한다.Another aspect of the present invention provides a cosmetic composition for enhancing skin elasticity or improving wrinkles, which comprises a canola extract or a fraction thereof as an active ingredient.
본 발명의 또 다른 양태로서 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공한다.As another embodiment of the present invention, there is provided a cosmetic composition for skin moisturizing comprising an extract of yu yin yang or a fraction thereof as an active ingredient.
본 발명의 또 다른 양태로서 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 트러블 개선용 화장료 조성물을 제공한다.As another embodiment of the present invention, there is provided a cosmetic composition for improving skin troubles comprising an extract of Yuan Yuan or a fraction thereof as an active ingredient.
본 발명의 또 다른 양태로서 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 식품 조성물을 제공한다.As another embodiment of the present invention, there is provided a food composition comprising a canola extract or a fraction thereof as an active ingredient.
본 발명의 또 다른 양태로서 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 의약외품 조성물을 제공한다.As another embodiment of the present invention, there is provided a quasi-drug composition comprising a canola extract or a fraction thereof as an active ingredient.
이하 본 발명을 구체적으로 설명한다. Hereinafter, the present invention will be described in detail.
본 발명에서는 용안육 추출물 또는 이의 분획물을 포함하는 조성물을 제공한다.The present invention provides a composition comprising a canola extract or a fraction thereof.
본 발명에 있어서, 용안육 (Longanae Arillus)은 용안 (龍眼) Dimocarpus longan Loureiro (무환자과 Sapindaceae)의 헛씨껍질로서, 구체적으로 무환자나무과(Sapindaceae)의 상록교목이고 열매의 용안의 과육을 말한다. 즉 과육같이 보이는 투명한 가종피(arillus)이며 마르면 검은 갈색인 용안육(Lonaganae Arillus)이 된다. 이러한 용안육은 주로 중국, 동남아 지역에 분포, 자생하며, 진정, 건위, 자양작용이 있으며, 불면증에 효과가 있다. 용안육 이외에 계원(桂圓), 교루(鮫淚), 밀비(蜜脾), 아려지(亞枝), 여주(驪珠), 연란(燕卵), 용목(龍目), 용안(龍眼), 용안건(龍眼乾), 원안(圓眼), 원안육(元眼肉), 익지(益智),천탄자(川彈子), 여지노(枝奴)로 명명될 수 있다.In the present invention, yonganyuk (Longanae Arillus is a dragon eye Dimocarpus longan Loureiro (Sapphire and Sapindaceae), specifically the evergreen tree of the Sapindaceae and refers to the pulp of the fruit of the fruit. That is to say, the transparent pulp ( arillus ) appears to be pulpy, and when dried, it becomes a black brown lonaganae arillus . These yongtan are mainly distributed in China and Southeast Asia, are native, have calming, dryness, nourishment, and are effective in insomnia. In addition to Yongan, it is also known as Kwangwen, Shark 淚, Milby, Arjie, Yeoju, Yan, Dragon 龍, Yongan, It can be named as an agan, an uan, an original 肉, an 益 智, a 子 子, a 지).
본 발명에서 사용되는 용어, "추출물"은 상기 용안육의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.The term "extract" used in the present invention refers to an extract obtained by the extraction treatment of the eye lotion, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, a preparation or a purified product of the extract, , The extract itself and extracts of all the formulations that can be formed using the extract.
본 발명의 상기 추출물은, 상기 각각의 해당 식물의 천연, 잡종 또는 변종 식물로부터 추출될 수 있고, 식물 조직 배양물로부터도 추출이 가능하다.The extract of the present invention can be extracted from natural, hybrid, or mutant plants of the respective plants, and can also be extracted from plant tissue cultures.
본 발명의 상기 용안육의 추출에 있어서, 상기 추출물을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다.In extracting the eye lyocaine of the present invention, the method for extracting the extract is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be performed alone or in combination with two or more methods.
본 발명에서 상기 용안육을 추출하는데 사용되는 추출용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 C1 내지 C4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게, 물, 저급알코올, 1,3-부틸렌글리콜, 에틸아세테이트를 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있다. The kind of the extraction solvent used for extracting the eyeball in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; C1 to C4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; And hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture thereof. Water, lower alcohol, 1,3-butylene glycol, and ethyl acetate may be used alone or in admixture of two or more.
본 발명에서 용안육의 한약재를 추출하는 용매로 보다 바람직하게는 물(또는 증류수)을 사용할 수 있다. 상기 용매를 사용하여 용안육의 한약재를 1회 이상 추출하여 용매 추출물을 제조할 수 있으며, 상기 용매 추출물을 감압 증류한 후 동결건조 또는 분무 건조하여 얻은 건조 추출물을 제조할 수 있다. 본 발명의 구체적인 일 실시예에서는 물(또는 증류수)를 사용하여 용안육의 추출물을 제조하였다(실시예 1).In the present invention, water (or distilled water) may be more preferably used as a solvent for extracting medicinal herbs of canned fish. The herbal medicines of the yongcheng can be extracted more than once by using the above solvent to prepare a solvent extract, and the dry extract obtained by vacuum distillation of the solvent extract, followed by lyophilization or spray drying can be prepared. In one specific embodiment of the present invention, water (or distilled water) was used to prepare an extract of canine yogurt (Example 1).
본 발명에서 열수 추출 또는 냉침 추출한 추출물은 부유하는 고체 입자를 제거하기 위해 여과, 예를 들어 나일론 등을 이용해 입자를 걸러내거나 냉동여과법 등을 이용해 여과한 후, 그대로 사용하거나 이를 동결건조, 열풍건조, 분무건조 등을 이용해 건조시켜 사용할 수 있다.In the present invention, the extract obtained by hot water extraction or cold extraction is filtered to remove suspended solid particles by filtration, for example, nylon or the like, or by freeze filtration, Spray drying and the like.
본 발명에서 사용되는 용어, "분획물"은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다.The term "fraction " as used herein means a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
본 발명에서 상기 분획물을 얻는 분획 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 수행될 수 있다. 상기 분획 방법의 비제한적인 예로는, 용안육을 추출하여 얻은 추출물에 소정의 용매를 처리하여 상기 추출물로부터 분획물을 얻는 방법을 들 수 있다.The fractionation method for obtaining the fraction in the present invention is not particularly limited and may be carried out according to a method commonly used in the art. As a non-limiting example of the above-mentioned fractionation method, there can be enumerated a method of obtaining a fraction from the extract by treating a predetermined solvent with the extract obtained by extracting the eye lotion.
본 발명에서 상기 분획물을 얻는 데에 사용되는 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매의 비제한적인 예로는 물, 알코올 등의 극성 용매; 헥산 (Hexane), 에틸아세테이트 (Ethyl acetate), 클로로포름 (Chloroform), 디클로로메탄(Dichloromethane) 등의 비극성 용매 등을 들 수 있다. 이들은 단독으로 사용되거나 2 종 이상 혼합하여 사용될 수 있다. 상기 분획 용매 중 알코올을 사용하는 경우에는 구체적으로는 C1 내지 C4의 알코올을 사용할 수 있다.The kind of the solvent used for obtaining the fraction in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fraction solvent include polar solvents such as water and alcohol; And non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more. When an alcohol is used in the fraction solvent, specifically C1 to C4 alcohols can be used.
본 발명은 용안육 추출물 또는 이의 분획물을 포함하는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition comprising a canola extract or a fraction thereof.
또한, 구체적으로, 본 발명은 용안육 추출물 또는 이의 분획물을 포함하는, 피부 탄력 증진 또는 주름 개선용, 피부 보습용, 또는 피부 트러블 개선용 화장료 조성물을 제공할 수 있다.Specifically, the present invention can provide a cosmetic composition for skin elasticity enhancement or wrinkle improvement, skin moisturizing, or skin trouble improvement comprising a canola extract or a fraction thereof.
본 발명에 있어서, “피부 탄력 증진”이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것으로, 엘라스틴으로 구성된 탄력섬유가 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력이 유지되는 것을 말한다. 본 발명에 있어서, “주름 개선”이란 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present invention, " skin elasticity enhancement " is intended to alleviate the degree to which the skin is stuck or stretched. Elastic fibers composed of elastin are present together with collagen fibers called collagen. Skin elasticity is maintained. In the present invention, " wrinkle improvement " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.
본 발명의 일 실시예에서는, 용안육 추출물을 인간 유래 섬유아세포의 배양액에 첨가한 후 콜라겐 합성 촉진 효과를 실험한 결과, 상기 화합물을 첨가한 실험군의 경우 대조군과 비교해 우수한 콜라겐 합성 효과를 나타내었다(표 3). 또한, 본 발명의 일 실시예에서는 용안육 추출물의 엘라스타제 활성 저해 효과를 실험한 결과, 용안육 추출물을 첨가한 실험군의 경우 우수한 엘라스타제 활성 저해 효과를 나타냄을 확인하였다(표 4). 이를 통해 본 발명의 용안육 추출물을 포함하는 조성물은 피부 탄력 증진 또는 주름 개선 용도로 사용될 수 있음을 확인하였다.In one embodiment of the present invention, the effect of promoting collagen synthesis after the addition of the Yonggak extract to the culture medium of human-derived fibroblasts was found to show an excellent collagen synthesis effect as compared with the control group 3). In addition, in an embodiment of the present invention, it was confirmed that the extract of Yongtan extract inhibited the elastase activity of the Yongtan extract, and the test group of Yongtan extract showed the excellent inhibitory effect of elastase activity (Table 4). Thus, it was confirmed that the composition containing the extract of the eye drop of the present invention can be used for skin elasticity enhancement or wrinkle improvement.
본 발명에 있어서, “피부 보습”이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 피부 보습 효과는 피부의 주름개선, 탄력도 증가에 도움을 줄 수 있다. 본 발명의 용안육 추출물의 우수한 콜라겐 합성 효과, 및 엘라스타제 활성 저해 효과를 나타내었는바, 이로부터 본 발명의 용안육 추출물을 포함하는 조성물은 피부 보습 용도로 사용될 수 있음을 확인하였다(표 2 내지 4).In the present invention, " skin moisturizing " means increasing moisture in the skin and maintaining a moist state. Skin moisturizing effect can help to improve wrinkles and elasticity of skin. The collagen synthesis effect and the elastase activity inhibition effect of the canine leukocyte extract of the present invention were shown, and it was confirmed that the composition containing the canine leukocyte extract of the present invention can be used for skin moisturizing (Tables 2 to 4 ).
본 발명에 있어서, “피부 트러블”이란 대식세포에서의 과도한 일산화질소 생성으로 인하여 유발된 염증에 의해 발생할 수 있는 피부질환을 의미한다. 상기 피부 트러블은 염증과 관련된 피부질환이면 그 종류에 관계없이 모두 포함되며, 상기 염증과 관련된 피부질환의 비제한적인 예로는 아토피 피부염, 건선, 방사선, 화학물질, 화상 등에 의해 촉발되는 홍반성 질환, 산 화상, 수포성 피부병, 태선 모양 종류 질환, 알레르기에 기한 가려움증, 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염, 원형 탈모증과 같은 염증성 모발 손실, 피부 T-세포 림프종 등이 있으며, 구체적으로, 피부발진, 여드름, 뾰루지, 주사(빨간 코) 등이 있으나 이에 제한되는 것은 아니다. 또한, 본 발명에서 사용되는 용어, "트러블 개선"이란 피부에 트러블이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 트러블을 완화시키는 것을 말한다. In the present invention, " skin trouble " means a skin disease that can be caused by inflammation caused by excessive nitric oxide production in macrophages. The skin trouble includes all kinds of skin diseases related to inflammation regardless of the type thereof. Non-limiting examples of the skin diseases related to the inflammation include inflammatory diseases caused by atopic dermatitis, psoriasis, radiation, chemical substances, Inflammatory hair loss such as acid burns, watery skin diseases, psoriasis type diseases, allergic itching, seborrheic eczema, rose acne, pemphigus vulgaris, polymorphic exudative erythema, erythema nodosum, Cell lymphoma, and the like. Specific examples include skin rash, acne, rash, injection (red nose), but are not limited thereto. The term "improvement of trouble" as used in the present invention refers to inhibiting or inhibiting the generation of troubles in the skin or alleviating troubles already generated.
본 발명에 있어서, “항염증”이란 염증을 억제하는 것을 말하며, 상기 염증은 어떤 자극에 대한 생체조직의 방어반응의 하나로, 조직 변질, 순환 장애와 삼출, 조직 증식의 세가지를 병발하는 복잡한 병변을 말한다. 보다 구체적으로 염증은 선천성 면역의 일부이며 다른 동물에서처럼 인간의 선천성 면역은 병원체에 특이적으로 존재하는 세포 표면의 패턴을 인식한다. 식세포는 그런 표면을 가진 세포를 비자기로 인식하고 병원체를 공격한다. 만일 병원균이 신체의 물리적 장벽을 깨고 들어온다면 염증반응이 일어난다. 염증반응은 상처부위에 침입한 미생물들에 대한 적대 환경을 만드는 비특이적인 방어작용이다. 염증반응에서, 상처가 나거나 외부 감염체가 체내로 들어왔을 때, 초기단계 면역반응을 맡고 있는 백혈구들이 몰려들어 사이토카인을 발현한다. 따라서 세포 내 사이토카인의 발현양이 염증반응 활성화의 지표가 된다. 본 발명의 항염증은 피부에서 발병된 염증을 억제하는 것일 수 있다.In the present invention, " anti-inflammation " refers to inhibition of inflammation. The inflammation is a defense reaction of biological tissue against a certain stimulus, and includes complicated lesions involving tissue degeneration, circulatory disorder and exudation, and tissue proliferation. It says. More specifically, inflammation is part of congenital immunity and, like in other animals, human congenital immunity recognizes a pattern of cell surfaces that are specifically present in a pathogen. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory reaction occurs. Inflammation is a nonspecific defense that creates hostile environments for microorganisms entering the wound. In the inflammatory response, white blood cells that are responsible for the early stage of immune response, when wounded or infected, enter the body to express cytokines. Therefore, the expression level of intracellular cytokine is an index of inflammatory response activation. The antiinflammation of the present invention may be to suppress inflammation caused in the skin.
본 발명의 일 실시예에서는, 용안육 추출물의 NO 생성 억제력을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 양성대조군에 상응하는 정도의 항염증 효과를 나타내었다. 이를 통해 본 발명의 용안육 추출물을 포함하는 조성물은 피부 트러블 개선 용도로 사용될 수 있으며, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용할 수 있음을 확인하였다(표 5).In one embodiment of the present invention, the inhibitory potency of NO production of Yongcheng extract showed that anti-inflammatory effect of the test group to which the compound was added was comparable to that of the positive control group. Thus, it was confirmed that the composition containing the eye drop of the present invention can be used for improving skin troubles and can act as an auxiliary role in skin whitening, elasticity enhancement, wrinkle improvement, and skin moisturization (Table 5).
본 발명에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention can be used as a cosmetic composition in the form of a solution, an ointment for external use, a cream, a foam, a nutritional lotion, a softening water, a pack, a soft water, an emulsion, a makeup base, But are not limited to, emulsions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays It is not.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier to be incorporated in a general skin cosmetic composition, and examples thereof include oil, water, a surfactant, a moisturizer, A thickening agent, a chelating agent, a coloring matter, an antiseptic, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, a paste, a cream or a gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide Mixtures of these may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as the carrier component, Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil may be used, in particular fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycols or sorbitan may be used have.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, glycerol, .
본 발명의 화장료 조성물에서, 용안육 추출물은 구체적으로는 건조 중량으로, 화장료 조성물 총 중량의 0.0001 내지 50 중량%로 포함될 수 있으며, 보다 구체적으로는 0.0005 내지 10 중량%로 포함될 수 있다. 상기 범위 내에서 우수한 피부 탄력 증진 또는 주름 개선용; 피부 보습용; 또는 피부 트러블 개선 효능을 나타내는 이점이 있으며, 조성물의 제형이 안정화되는 이점이 있다.In the cosmetic composition of the present invention, the yin yang extract may be contained in an amount of 0.0001 to 50 wt%, more specifically 0.0005 to 10 wt%, based on the total weight of the cosmetic composition, in terms of dry weight. Good skin elasticity or wrinkle improvement within the above range; For skin moisturizing; Or an effect of improving the skin trouble, and there is an advantage that the formulation of the composition is stabilized.
본 발명의 다른 양태로서 용안육 추출물 또는 이의 분획물을 포함하는 식품 조성물을 제공한다.Another aspect of the present invention provides a food composition comprising a canola extract or a fraction thereof.
또한, 구체적으로, 본 발명은 용안육 추출물 또는 이의 분획물을 포함하는 피부 탄력 증진 또는 주름 개선용; 피부 보습용; 또는 피부 트러블 개선용 식품 조성물을 제공할 수 있다. More specifically, the present invention relates to a composition for enhancing skin elasticity or improving wrinkles, comprising a canola extract or a fraction thereof; For skin moisturizing; Or a food composition for improving skin troubles can be provided.
본 발명의 용안육 추출물, 피부 탄력 증진, 주름 개선, 피부 보습, 및 피부 트러블 개선은 상기에서 설명한 바와 같다. 상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되는 것은 아니다.The eyelash extract of the present invention, skin elasticity enhancement, wrinkle improvement, skin moisturization, and skin trouble improvement are as described above. The food composition may be used in the form of a health functional food, but is not limited thereto.
본 발명의 식품 조성물에 포함된 용안육 추출물 또는 이의 분획물은 본 발명의 용안육 추출물을 포함하는 동식물, 이의 추출물, 이의 분획물 또는 이의 가공물의 형태로 포함될 수 있다. 또한 상기 조성물은 유효성분 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The canine extract or its fractions contained in the food composition of the present invention may be contained in the form of an animal or animal including the canine extract of the present invention, an extract thereof, a fraction thereof or a processed product thereof. The composition may also include a food-acceptable food-aid additive in addition to the active ingredient.
본 발명에 있어서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.In the present invention, the term "food-aid additive " means a component that can be added to foods in a supplementary manner, and is appropriately selected and used by those skilled in the art as added to produce health functional foods of each formulation. Examples of food-aid additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, , a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, and a carbonating agent used in a carbonated drink. However, the types of the food auxiliary additives of the present invention are not limited by these examples.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 “기능성”이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부 탄력 증진 또는 주름 개선, 피부 보습, 또는 피부 트러블 개선 효과를 증진시키기 위한 보조제로 섭취가 가능하다.A health functional food may be included in the food composition of the present invention. In the present invention, the term "health functional food" refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. The term "functional" as used herein means that the structure and function of the human body have a beneficial effect on health uses such as controlling nutrients or physiological actions. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The food composition of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has an advantage of being free from side effects that may occur when a food is used as a raw material for a long period of time, and is excellent in portability. The health functional food can be supplemented as an adjuvant to improve skin elasticity or improve wrinkle, skin moisturizing, or skin trouble improving effect.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 화학식 1로 표시되는 화합물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.The form of the health functional food of the present invention is not limited, and may include all foods in the conventional meaning, and may be used in combination with terms known in the art such as functional foods. In addition, the health functional food of the present invention can be prepared by mixing other suitable auxiliary ingredients, which may be included in food, according to the selection of a person skilled in the art, and known additives. Examples of foods that can be added include dairy products, such as meat, sausage, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Vitamin complex, and the like, and can be prepared by adding to juice, tea, jelly, juice and the like prepared by using the compound represented by the formula (1) according to the present invention as a main component. It also includes foods used as feed for animals.
본 발명의 또 다른 양태로서 용안육 추출물 또는 이의 분획물을 포함하는 의약외품 조성물을 제공한다.Another aspect of the present invention provides a quasi-drug composition comprising a canola extract or a fraction thereof.
또한, 구체적으로, 본 발명은 용안육 추출물 또는 이의 분획물을 포함하는 피부 탄력 증진 또는 주름 개선용; 피부 보습용; 또는 피부 트러블 개선용 의약외품 조성물을 제공할 수 있다. 본 발명의 용안육 추출물, 피부 탄력 증진, 주름 개선, 피부 보습, 및 피부 트러블 개선은 상기에서 설명한 바와 같다.More specifically, the present invention relates to a composition for enhancing skin elasticity or improving wrinkles, comprising a canola extract or a fraction thereof; For skin moisturizing; Or a quasi-product composition for improving skin troubles can be provided. The eyelash extract of the present invention, skin elasticity enhancement, wrinkle improvement, skin moisturization, and skin trouble improvement are as described above.
본 발명의 의약외품 조성물에는 상기 성분 외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.The quasi-drug composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent as necessary in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, .
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium Methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oils such as sodium carboxymethylcellulose, , Injectable ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper.
또한, 본 발명의 용안육 추출물을 의약외품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 탄력 증진, 주름 개선, 보습, 또는 항염증 성분을 포함할 수 있을 것이다. 추가적인 탄력 증진, 주름 개선, 보습, 또는 항염증 성분을 포함하게 되면 본 발명의 조성물의 탄력 증진, 주름 개선, 보습, 또는 피부 트러블 개선 효과는 더욱 증가될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 상기 의약외품 조성물은 당업계에 공지된 당업계에 공지된 피부 탄력, 주름 개선 또는 보습 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물; 당업계에 공지된 항염증 성분으로서, 비스테로이드계로 플루페남산, 이부프로펜, 벤지다민, 인도메타신, 프레드니솔론, 덱사메타손, 알란토인, 아즈엔, 하이드로코티손; 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 피부 안전성, 본 발명의 용안육 추출물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.In addition, when the canine eyelash extract of the present invention is used as a quasi-drug, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may contain known elasticity enhancement, wrinkle improvement, moisturizing, or anti-inflammatory components. When the composition contains additional elasticity enhancement, wrinkle improvement, moisturizing, or anti-inflammatory component, the effect of improving the elasticity, wrinkle, moisturizing, or skin trouble of the composition of the present invention may be further increased. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. The quasi-drug composition includes retinoic acid, TGF, an animal placenta-derived protein, betulinic acid and chlorella extract, skin elasticity, wrinkle-improving or moisturizing ingredients well known in the art; As anti-inflammatory ingredients known in the art, there are non-steroid based flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, dexamethasone, allantoin, azene, hydrocortisone; And derivatives thereof, and various plant extracts. ≪ Desc / Clms Page number 2 > The additional ingredient may be contained in an amount of 0.0001 to 10% by weight based on the total weight of the composition, and the content may be adjusted according to requirements such as skin safety, ease of formulation of the eye drop of the present invention, and the like.
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention can be exemplified by a disinfectant cleaner, a shower foam, a softener solution, a wet tissue, a coating agent, and the like. The formulation method, dosage, usage method, And the like.
또한, 본 발명의 용안육 추출물은 개체의 피부에 도포하는 단계를 포함하는, 피부 탄력 증진 또는 주름 개선, 피부 보습, 또는 피부 트러블 개선 방법에 사용될 수 있다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함한다.In addition, the eye drop extract of the present invention can be used in a method for improving skin elasticity or improving wrinkles, skin moisturizing, or skin troubles, including a step of applying to the skin of an individual. The subject includes, without limitation, mammals including rats, livestock, humans, and the like.
본 발명의 용안육 추출물 또는 이의 분획물을 유효성분으로 포함하는 화장료 조성물은 탄력 증진 또는 주름 개선, 피부 보습, 피부 트러블 개선 효능이 우수하다. 구체적으로 본 발명의 조성물은 엘라스타제 활성 저해 효과가 우수하며, 항염증 및 보습 효과가 우수하여 탄력 증진용 또는 주름 개선용, 피부 보습용, 및 피부 트러블 개선용 화장료 조성물로서의 활용도가 높다. 또한, 본 발명의 용안육 추출물 또는 이의 분획물을 포함하는 조성물은 식품 조성물 및 의약외품 조성물로서 사용할 수 있다.The cosmetic composition comprising the canine leavening extract of the present invention or a fraction thereof as an active ingredient is excellent in improvement in elasticity or wrinkle, skin moisturizing effect, and skin trouble-improving effect. Specifically, the composition of the present invention is excellent in anti-elastase activity and excellent in anti-inflammation and moisturizing effect, so that it is highly utilized as a cosmetic composition for improving elasticity or wrinkle, skin moisturizing, and skin trouble improvement. In addition, the composition containing the canine luciferase extract or the fraction thereof of the present invention can be used as a food composition and a quasi-drug composition.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the constitution and effects of the present invention will be described in more detail through examples. These embodiments are only for illustrating the present invention, and the scope of the present invention is not limited by these embodiments.
실시예Example 1 : One : 용안육Yonggak 추출물의 제조 Preparation of extract
용안육을 건조하여 세절(細切)한 후, 건조 중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침한 추출물을 0.2㎛ 기공 크기를 갖는 필터로 여과하여 용안육 추출물을 제조하였다.The pellets were dried and finely cut, and then 100 g of dry weight was put into a flask and extracted with 1000 g of an extraction solvent (distilled water) for 3 days by cooling. The frozen extract was filtered with a filter having a pore size of 0.2 μm to prepare a canola extract.
실시예Example 2 : 에센스 제조 2: Essence manufacturing
실시예 1의 용안육 추출물을 포함하는 에센스를 제조하였다. 상세한 조성(중량%)는 하기 표 1에 나타내었다.An essence containing the lucerne extract of Example 1 was prepared. The detailed composition (% by weight) is shown in Table 1 below.
주1. 카르복시비닐폴리머 - 미국 비.에프.굿리치(B.F.Goodrich)사의 카보폴 941(Carbopol 941) 1 중량% 수용액Note 1 . Carboxyvinyl polymer - a 1% by weight aqueous solution of Carbopol 941 from BF Goodrich, USA
주2. 모노스테아린산소르비탄 - 영국 아이시아이(ICI)사이 아라셀 60(Arlacel 60)Note 2 . Monostearic acid sorbitan - ICI Sialasel 60 (Arlacel 60)
주3. 이소세틸옥타노에이트 - 일본 니혼 고쿄 알코올(Nihon KoKyu Alcohol)사의 아이시이에이치(ICEH) Note 3 . Isocetyl Octanoate - Ishihi (ICEH) of Nihon KoKyu Alcohol Co.,
비교예Comparative Example 1 : One : 용안육Yonggak 추출물을 포함하지 않는 에센스 Essence without extracts
용안육 추출물을 포함하지 않는 것을 제외하고는 실시예 2와 동일하게 제조하였다. The extract was prepared in the same manner as in Example 2, except that the extract of yunnan was not included.
실험예Experimental Example 1 : 수분 1: moisture 보유능Possession 평가 evaluation
실시예 2 및 비교예 1의 에센스의 피부 보습력을 평가하기 위하여 상기 실시예 2 및 비교예 1의 에센스를 각각 피부에 정량 도포한 후 각질층의 수분 보유량을 측정하고 이를 평가하는 방법을 사용하였다. In order to evaluate the skin moisturizing power of the essence of Example 2 and Comparative Example 1, the essence of Example 2 and Comparative Example 1 was applied to the skin, respectively, and then the moisture content of the stratum corneum was measured and evaluated.
측정 기기로는 피부수분함량 측정기(스킨 설피스 하이그로미터, skin surface hygrometer, 모델명: SKICON-200, 일본 IBS사 제품)를 이용하였다. As a measuring device, a skin moisture meter (skin surface hygrometer, model name: SKICON-200, manufactured by IBS Japan) was used.
구체적으로 25℃, 상대습도 45의 항온 항습실에서 실시예 2 및 비교예 1의 에센스를 각각 20명의 피시험자의 팔의 안쪽에 일정량(2 mg/㎠) 도포한 후 잘 문지르고, 평가 전의 수분 보유능을 기준으로 1시간과 3시간 후의 수분 증가율(%)을 측정하여 보습 효과를 평가하였다. 얻어진 결과를 하기 표 2에 나타내었다.Specifically, the essences of Example 2 and Comparative Example 1 were applied to a predetermined amount (2 mg / cm 2) of the inside of each arm of 20 subjects in a constant temperature and humidity room at 25 ° C and a relative humidity of 45, and rubbed well. The moisture increase rate (%) after 1 hour and 3 hours was measured to evaluate the moisturizing effect. The obtained results are shown in Table 2 below.
상기 표 2에 나타낸 바와 같이, 본 발명의 실시예 2의 에센스는 비교예 1의 에센스에 비해 도포 1시간 후 및 3시간 후의 수분 보유 증가율이 높은 바 보습 효과가 우수함을 알 수 있었다As shown in Table 2, the essence of Example 2 of the present invention was superior to the essence of Comparative Example 1 in that the water retention increase rate was high at 1 hour and 3 hours after application,
실험예Experimental Example 2 : 인체 유래의 섬유아세포에서 제1형 콜라겐(type Ⅰ collagen) 합성 촉진 효과 2: promoting the synthesis of type I collagen in human fibroblasts
실시예 1의 용안육 추출물을 인간 유래 섬유아세포의 배양액에 첨가하여 세포 수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type Ⅰ C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다. 콜라겐 합성량을 측정하기 위해 용안육 추출물을 섬유아세포의 배양배지(DMEM 배지)에 첨가하여 48 시간 배양한 후 배양액을 취하여 PICP EIA 키트로 각 농도에서 제1형 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다.The canine extract of Example 1 was added to the culture medium of human-derived fibroblasts to confirm the promoting effect of type I collagen synthesis at the cellular level. The collagen synthesis was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay Kit). In order to measure the amount of collagen synthesis, the Yongin extract was added to a culture medium of fibroblasts (DMEM medium) and cultured for 48 hours. The culture broth was taken and the degree of collagen type I collagen synthesis was measured with a PICP EIA kit at 450 nm.
효과의 비교를 위하여 용안육 추출물을 처리하지 않은 섬유아세포의 배양배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 ㎍/㎖가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성 증가율은 음성대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 3에 나타내었으며, 실험은 4회씩 수행하여 평균값으로 나타내었다.For comparison of the effects, the degree of collagen synthesis was measured in the same manner as in the case of the culture medium (negative control) and the vitamin C (positive control) added to the final concentration of 52.85 / / ㎖ of the fibroblasts without treatment with the Yongin extract . The increase rate of collagen production was calculated as a ratio of relative collagen production to negative control, and the results are shown in Table 3 below.
상기 표 3의 결과에서 볼 수 있듯이, 실시예 1의 용안육 추출물을 처리한 경우, 농도 의존적으로 콜라겐 합성이 증가되었고, 용안육 추출물이 콜라겐 합성에 효과가 있음을 알 수 있었다. 따라서, 실시예 1의 용안육 추출물은 피부 탄력 증진, 주름 개선 또는 피부 보습 용도로 사용할 수 있음을 알 수 있었다. As can be seen from the results of Table 3 above, the collagen synthesis was increased in a concentration-dependent manner when the extract of the eye drop of Example 1 was treated, and that the extract of Yongtan extract was effective in collagen synthesis. Therefore, it was found that the eye drop extract of Example 1 can be used for skin elasticity enhancement, wrinkle improvement or skin moisturizing.
실험예Experimental Example 3 : 3: 엘라스타제Elastase 활성 저해 효과 ( Active inhibition effect ( 반복수Number of repeats = 3) = 3)
엘라스틴(elastin)을 분해하는 효소인 엘라스타제(elastase)의 활성 저해 효과를 다음과 같이 확인하였다.The activity inhibition effect of elastase, an enzyme that degrades elastin, was confirmed as follows.
엘라스타제(elastase)는 사람의 백혈구 세포로부터 유래한 것을 사용하였고, 엘라스타제의 기질로 합성 기질인 MeOSuc-Ala-Ala-Pro-Val-pNA를 사용하였다. 완충용액은 100 mM의 Tris (pH 7.5) 용액을 사용하였다. 엘라스타제는 완충용액을 이용하여 최종적으로 0.2 mU을 사용하였다. 또한 엘라스타제의 합성 기질은 DMSO를 이용하여 100 mM 용액을 만든 후 최종 농도가 0.5 mM이 되도록 완충용액을 이용하여 희석하였다. 이 때, 양성대조군은 엘라스타제 저해 물질로 알려진 퀘르세틴(Quercetin)을 10 ppm 농도로 넣은 것으로 설정하였다. 엘라스타제 저해 후보인 실시예 1의 용안육 추출물은 최종농도가 1000, 10000 ppm이 되도록 첨가하였다. 반응은 96-웰 플레이트에서 진행하였으며, 상온에서 20 분간 반응시켰다. 분광 광도계를 이용하여 1 분 간격으로 405 nm에서 흡광도를 측정하여, 시간 대비 흡광도의 기울기를 구하여 효소의 활성도를 측정하였다. 엘라스타제 저해율은 하기 수학식 1과 같이 계산하였으며, 그 결과는 하기 표 4에 나타내었으며, 실험은 각각 3회씩 수행하여 평균값으로 나타내었다.Elastase was derived from human leukocyte cells and MeOSuc-Ala-Ala-Pro-Val-pNA, a synthetic substrate, was used as a substrate for elastase. The buffer solution used was 100 mM Tris (pH 7.5) solution. Elastase was finally used at 0.2 mU using a buffer solution. The synthetic substrate of elastase was diluted with buffer to make a final concentration of 0.5 mM after making 100 mM solution using DMSO. At this time, the positive control group was set to contain 10 ppm of quercetin, which is known as an elastase inhibitor. The extract of the eye lentil of Example 1, which is a candidate for inhibition of elastase, was added so as to have a final concentration of 1000, 10000 ppm. The reaction was carried out in a 96-well plate and allowed to react at room temperature for 20 minutes. The absorbance was measured at 405 nm using a spectrophotometer at intervals of 1 minute, and the slope of the absorbance versus time was measured to determine the activity of the enzyme. Elastase inhibition rate was calculated according to the following Equation 1, and the results are shown in Table 4 below.
[수학식 1][Equation 1]
상기 표 4의 결과에서 볼 수 있듯이, 실시예 1의 용안육 추출물은 대조군에 비해 뛰어난 엘라스타제 활성 저해 효과를 보임을 확인하였다. 따라서, 실시예 1의 용안육 추출물은 피부 탄력 증진, 주름 개선 또는 피부 보습 용도로 사용할 수 있음을 알 수 있었다. As can be seen from the results of Table 4, it was confirmed that the extract of yangyang extract of Example 1 showed an excellent inhibitory effect on elastase activity as compared with the control group. Therefore, it was found that the eye drop extract of Example 1 can be used for skin elasticity enhancement, wrinkle improvement or skin moisturizing.
실험예Experimental Example 4 : 항염증 효과 - NO 생성 억제 효과 4: Anti-inflammatory effect - NO production inhibitory effect
실시예 1의 용안육 추출물의 항염증 효과 및 피부 트러블 개선 효과를 확인하기 위하여 RAW264.7 세포주 (ATCC number: CRL-2278)를 이용한 GRIESS 법으로 일산화질소(NO) 형성 억제 실험을 실시하였다.In order to confirm the antiinflammatory effect and the skin trouble improving effect of the eye drop extract of Example 1, a nitric oxide (NO) formation inhibition experiment was carried out by the GRIESS method using the RAW264.7 cell line (ATCC number: CRL-2278).
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대 배양하고, 상기 배양된 세포를 웰 하나에 3×105 개씩 들어가도록 24-웰 플레이트에 넣은 후, 24 시간 동안 배양하였다. 이어서, 하기 표 5에 나타난 농도로 희석된 실시예 1의 용안육 추출물을 함유한 세포 배지로 교체하였다. 이 때, NO-생성 억제물질인 L-NMMA(L-NG-모노메틸아르기닌, L-NG-Monomethylarginine)을 양성대조군으로 함께 처리하여 30분 동안 배양하였고, 자극원으로 LPS(Lipopolysaccharide)를 1 ㎍씩 처리하여 24시간 동안 배양하였다. 상층액을 100 ㎕씩 취해 96-웰 프레이트에 옮기고, GRIESS 용액을 100 ㎕씩 가해 상온에서 10분간 반응시킨 후, 540 nm에서의 흡광도를 측정함으로써 용안육 추출물의 NO 억제 효과를 판단하였다. NO 생성 저해율(%)는 하기 수학식 2를 이용하여 계산하여 그 결과를 하기 표 5에 나타내었으며, 실험은 각각 3회씩 수행하여 평균값으로 나타내었다.Specifically, mouse macrophages RAW264.7 cells were subcultured several times, and the cultured cells were put into a 24-well plate so as to enter 3x10 5 wells into one well, followed by culturing for 24 hours. Then, the cell culture medium containing the lucerolytic extract of Example 1 diluted to the concentration shown in Table 5 below was replaced. At this time, L-NMMA (L-NG-monomethylarginine), a NO-production inhibitor, was treated together as a positive control and cultured for 30 minutes. Lipopolysaccharide (LPS) And cultured for 24 hours. 100 μl of the supernatant was transferred to a 96-well plate, and 100 μl of the GRIESS solution was added thereto at room temperature for 10 minutes. Then, the absorbance at 540 nm was measured to determine the NO inhibitory effect of the extract. The NO production inhibition rate (%) was calculated using the following equation (2), and the results are shown in Table 5 below.
[수학식 2]&Quot; (2) "
NO 생성 저해율(%)={(음성대조군의 흡광도 - 각 추출물의 흡광도)/음성 대조군의 흡광도} x 100 NO production inhibition rate (%) = {(absorbance of negative control - absorbance of each extract) / absorbance of negative control} x 100
상기 표 5의 결과에서 볼 수 있듯이, 실시예 1의 용안육 추출물은 대표적인 항염 물질로서 합성물질인 L-NMMA과 비교하였을 때, 천연물질로써 우수한 활성을 나타냄을 알 수 있었다. 따라서, 실시예 1의 용안육 추출물은 피부 트러블 개선 용도로 사용할 수 있으며, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다.As can be seen from the results shown in Table 5, the extract of the eye drop of Example 1 showed excellent activity as a natural substance when compared with the synthetic anti-inflammatory substance L-NMMA. Therefore, the eye drop extract of Example 1 can be used for improving skin troubles, and it can be expected that a synergistic effect can be expected by acting as an auxiliary role in skin whitening, elasticity enhancement, wrinkle improvement, and skin moisturization.
Claims (10)
A cosmetic composition comprising an extract of Yuan Yuan or a fraction thereof as an active ingredient.
The cosmetic composition of claim 1, wherein the composition is for enhancing skin elasticity or improving wrinkles.
The cosmetic composition of claim 1, wherein the composition is for skin moisturizing.
The cosmetic composition according to claim 1, wherein the composition is for improving skin troubles.
The cosmetic composition according to any one of claims 1 to 4, wherein the composition has collagen synthesis promotion, inhibition of elastase activity, moisturizing or anti-inflammatory effect.
The composition according to any one of claims 1 to 4, wherein the composition is selected from the group consisting of a solution, an external ointment, a cream, a foam, a nutritional lotion, a softening longevity pack, a pack, a soft water, a latex, a makeup base, an essence, , Sunscreen creams, sun oil, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays ≪ / RTI >
A food composition comprising an extract of Yuan Yuan or a fraction thereof as an active ingredient.
8. The composition of claim 7, wherein the food composition is for skin elasticity enhancement or wrinkle improvement; For skin moisturizing; Or for improving skin troubles.
A quasi-drug composition comprising a granulosa extract or a fraction thereof as an active ingredient.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160171795A KR101922089B1 (en) | 2016-12-15 | 2016-12-15 | Cosmetic Composition for comprising longanae arillus extracts |
| PCT/KR2017/014863 WO2018111042A2 (en) | 2016-12-15 | 2017-12-15 | Cosmetic composition comprising extract of medicinal herbs as active ingredient |
| JP2019532746A JP2020502172A (en) | 2016-12-15 | 2017-12-15 | Cosmetic composition containing Chinese herbal extract as active ingredient |
| US16/470,044 US20200078290A1 (en) | 2016-12-15 | 2017-12-15 | Cosmetic Composition Comprising Extract Of Medicinal Herbs As Active Ingredient |
| CN201780077517.2A CN110072516B (en) | 2016-12-15 | 2017-12-15 | Cosmetic composition comprising extracts of Chinese medicinal materials as effective ingredients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160171795A KR101922089B1 (en) | 2016-12-15 | 2016-12-15 | Cosmetic Composition for comprising longanae arillus extracts |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180060449A Division KR102126470B1 (en) | 2018-05-28 | 2018-05-28 | Cosmetic Composition for comprising longanae arillus extracts |
| KR1020180060448A Division KR102105672B1 (en) | 2018-05-28 | 2018-05-28 | Cosmetic Composition for comprising longanae arillus extracts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180069528A true KR20180069528A (en) | 2018-06-25 |
| KR101922089B1 KR101922089B1 (en) | 2018-11-26 |
Family
ID=62806231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160171795A KR101922089B1 (en) | 2016-12-15 | 2016-12-15 | Cosmetic Composition for comprising longanae arillus extracts |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101922089B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3085839A1 (en) * | 2018-09-13 | 2020-03-20 | Basf Beauty Care Solutions France Sas | USE OF PHYTOSTEROLS |
| CN115297880A (en) * | 2020-03-13 | 2022-11-04 | (株)美迪合伙来音 | Topical composition comprising extract of crude drug comprising arillus longan for treating or improving skin ulcer, and its application |
-
2016
- 2016-12-15 KR KR1020160171795A patent/KR101922089B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3085839A1 (en) * | 2018-09-13 | 2020-03-20 | Basf Beauty Care Solutions France Sas | USE OF PHYTOSTEROLS |
| CN115297880A (en) * | 2020-03-13 | 2022-11-04 | (株)美迪合伙来音 | Topical composition comprising extract of crude drug comprising arillus longan for treating or improving skin ulcer, and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101922089B1 (en) | 2018-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102126470B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| JP2020532560A (en) | Cosmetic composition containing extract of Dendrobium candidam flower | |
| KR102171133B1 (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
| KR20180119550A (en) | Cosmetic Composition for skin moisturizing comprising Aquilaria agallocha Roxburgh extracts | |
| KR102243982B1 (en) | Composition for improving skin troubles comprising mortierella oil as an active ingredient | |
| KR102425559B1 (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
| CN110072516B (en) | Cosmetic composition comprising extracts of Chinese medicinal materials as effective ingredients | |
| KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR101922089B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR100864915B1 (en) | Composition comprising mixed extract of japanese apricot and pear blossom having anti-oxidative activity | |
| KR102105672B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR20180090123A (en) | Composition for skin improvement containing liquidambaric lactone | |
| KR20180045626A (en) | Composition for skin improvement containing valechlorine | |
| KR20180069530A (en) | Cosmetic Composition for skin moisturizing comprising Aquilaria agallocha Roxburgh extracts | |
| KR20180082058A (en) | A cosmetic composition for skin desquamation comprising natural complex extract | |
| KR20180027213A (en) | Composition for skin improvement containing Salvianolic acid C | |
| KR20160061601A (en) | Cosmetic composition and pharmaceutical composition containing the extract of Corchorus olitorius L, ginko and chlorella | |
| KR102292114B1 (en) | Composition for Improving Skin Conditions Having Moisturizing, Anti-Inflammatory Caused by Fine Dust and Pore Shrinkage Property Comprising Plant Complex Extracts as Active Ingredient | |
| KR102366932B1 (en) | Composition with Antioxidant, Anti-Inflammation, Skin Moisturizing, Anti-Wrinkle, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus Softened Petal as Active Ingredient | |
| KR20130136602A (en) | Cosmetic composition from field waterdrop extract and its fermentation | |
| KR102145032B1 (en) | Cosmetic composition comprising mortierella oil | |
| KR20180061663A (en) | Composition for skin improvement containing dehydroevodiamine | |
| KR102700608B1 (en) | Composition for skin improvement containing rehmapicroside | |
| KR20180045625A (en) | Composition for skin improvement containing acetylcimigenol arabinoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |